2 results
Approved WMORecruiting
To assess the time to progression after TACE-DEB and after SBRT in a comparable population of patients diagnosed with HCC.
Approved WMOWill not start
Primary Objectives* Phase 1b lead-in: To assess safety and tolerability of a single dose level of avelumab in combination withincreasing dose levels of other immune modulators in combination with a single doselevel of avelumab in patients with…